Background: Elevated body mass index (BMI) is associated with increased risk of postmenopausal breast cancer. The underlying mechanisms, however, remain elusive. Methods: In a nested case-control study of 621 postmenopausal breast cancer case participants and 621 matched control participants, we measured 617 metabolites in prediagnostic serum. We calculated partial Pearson correlations between metabolites and BMI, and then evaluated BMI-associated metabolites (Bonferroni-corrected α level for 617 statistical tests = P < 8.10 × 10-5) in relation to invasive breast cancer. Odds ratios (ORs) of breast cancer comparing the 90th vs 10th percentile (modeled on a continuous basis) were estimated using conditional logistic regression while controlling for breast cancer risk factors, including BMI. Metabolites with the lowest P values (false discovery rate < 0.2) were mutually adjusted for one another to determine those independently associated with breast cancer risk. Results: Of 67 BMI-associated metabolites, two were independently associated with invasive breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.65, 95% confidence interval [CI] = 1.22 to 2.22) and 3-methylglutarylcarnitine (OR = 1.67, 95% CI = 1.21 to 2.30). Four metabolites were independently associated with estrogen receptor-positive (ER+) breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.84, 95% CI = 1.27 to 2.67), 3-methylglutarylcarnitine (OR = 1.91, 95% CI = 1.23 to 2.96), allo-isoleucine (OR = 1.76, 95% CI = 1.23 to 2.51), and 2-methylbutyrylcarnitine (OR = 1.89, 95% CI = 1.22 to 2.91). In a model without metabolites, each 5 kg/m2 increase in BMI was associated with a 14% higher risk of breast cancer (OR = 1.14, 95% CI = 1.01 to 1.28), but adding 16a-hydroxy-DHEA-3-sulfate and 3-methylglutarylcarnitine weakened this association (OR = 1.06, 95% CI = 0.93 to 1.20), with the logOR attenuating by 57.6% (95% CI = 21.8% to 100.0+%). Conclusion: These four metabolites may signal metabolic pathways that contribute to breast carcinogenesis and that underlie the association of BMI with increased postmenopausal breast cancer risk. These findings warrant further replication efforts.
Background: Elevated body mass index (BMI) is associated with increased risk of postmenopausal breast cancer. The underlying mechanisms, however, remain elusive. Methods: In a nested case-control study of 621 postmenopausal breast cancer case participants and 621 matched control participants, we measured 617 metabolites in prediagnostic serum. We calculated partial Pearson correlations between metabolites and BMI, and then evaluated BMI-associated metabolites (Bonferroni-corrected α level for 617 statistical tests = P < 8.10 × 10-5) in relation to invasive breast cancer. Odds ratios (ORs) of breast cancer comparing the 90th vs 10th percentile (modeled on a continuous basis) were estimated using conditional logistic regression while controlling for breast cancer risk factors, including BMI. Metabolites with the lowest P values (false discovery rate < 0.2) were mutually adjusted for one another to determine those independently associated with breast cancer risk. Results: Of 67 BMI-associated metabolites, two were independently associated with invasive breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.65, 95% confidence interval [CI] = 1.22 to 2.22) and 3-methylglutarylcarnitine (OR = 1.67, 95% CI = 1.21 to 2.30). Four metabolites were independently associated with estrogen receptor-positive (ER+) breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.84, 95% CI = 1.27 to 2.67), 3-methylglutarylcarnitine (OR = 1.91, 95% CI = 1.23 to 2.96), allo-isoleucine (OR = 1.76, 95% CI = 1.23 to 2.51), and 2-methylbutyrylcarnitine (OR = 1.89, 95% CI = 1.22 to 2.91). In a model without metabolites, each 5 kg/m2 increase in BMI was associated with a 14% higher risk of breast cancer (OR = 1.14, 95% CI = 1.01 to 1.28), but adding 16a-hydroxy-DHEA-3-sulfate and 3-methylglutarylcarnitine weakened this association (OR = 1.06, 95% CI = 0.93 to 1.20), with the logOR attenuating by 57.6% (95% CI = 21.8% to 100.0+%). Conclusion: These four metabolites may signal metabolic pathways that contribute to breast carcinogenesis and that underlie the association of BMI with increased postmenopausal breast cancer risk. These findings warrant further replication efforts.
Authors: Joshua N Sampson; Roni T Falk; Catherine Schairer; Steven C Moore; Barbara J Fuhrman; Cher M Dallal; Douglas C Bauer; Joanne F Dorgan; Xiao-Ou Shu; Wei Zheng; Louise A Brinton; Mitchell H Gail; Regina G Ziegler; Xia Xu; Robert N Hoover; Gretchen L Gierach Journal: Cancer Res Date: 2016-12-23 Impact factor: 12.701
Authors: Barbara J Fuhrman; Catherine Schairer; Mitchell H Gail; Jennifer Boyd-Morin; Xia Xu; Laura Y Sue; Saundra S Buys; Claudine Isaacs; Larry K Keefer; Timothy D Veenstra; Christine D Berg; Robert N Hoover; Regina G Ziegler Journal: J Natl Cancer Inst Date: 2012-01-09 Impact factor: 13.506
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Andrew C Shin; Martin Fasshauer; Nika Filatova; Linus A Grundell; Elizabeth Zielinski; Jian-Ying Zhou; Thomas Scherer; Claudia Lindtner; Phillip J White; Amanda L Lapworth; Olga Ilkayeva; Uwe Knippschild; Anna M Wolf; Ludger Scheja; Kevin L Grove; Richard D Smith; Wei-Jun Qian; Christopher J Lynch; Christopher B Newgard; Christoph Buettner Journal: Cell Metab Date: 2014-10-09 Impact factor: 27.287
Authors: Peter Würtz; Qin Wang; Antti J Kangas; Rebecca C Richmond; Joni Skarp; Mika Tiainen; Tuulia Tynkkynen; Pasi Soininen; Aki S Havulinna; Marika Kaakinen; Jorma S Viikari; Markku J Savolainen; Mika Kähönen; Terho Lehtimäki; Satu Männistö; Stefan Blankenberg; Tanja Zeller; Jaana Laitinen; Anneli Pouta; Pekka Mäntyselkä; Mauno Vanhala; Paul Elliott; Kirsi H Pietiläinen; Samuli Ripatti; Veikko Salomaa; Olli T Raitakari; Marjo-Riitta Järvelin; George Davey Smith; Mika Ala-Korpela Journal: PLoS Med Date: 2014-12-09 Impact factor: 11.069
Authors: Eline H van Roekel; Erikka Loftfield; Rachel S Kelly; Oana A Zeleznik; Krista A Zanetti Journal: Metabolomics Date: 2019-01-07 Impact factor: 4.290
Authors: Hua Zhao; Jie Shen; Steven C Moore; Yuanqing Ye; Xifeng Wu; Francisco J Esteva; Debasish Tripathy; Wong-Ho Chow Journal: Breast Cancer Res Treat Date: 2019-02-15 Impact factor: 4.872
Authors: Andreas Mock; Carmen Rapp; Rolf Warta; Amir Abdollahi; Dirk Jäger; Oliver Sakowitz; Benedikt Brors; Andreas von Deimling; Christine Jungk; Andreas Unterberg; Christel Herold-Mende Journal: Metabolomics Date: 2019-05-13 Impact factor: 4.290
Authors: Clary B Clish; Shelley S Tworoger; Oana A Zeleznik; A Heather Eliassen; Peter Kraft; Elizabeth M Poole; Bernard A Rosner; Sarah Jeanfavre; Amy A Deik; Kevin Bullock; Daniel S Hitchcock; Julian Avila-Pacheco Journal: Cancer Res Date: 2020-01-22 Impact factor: 12.701
Authors: Alvaro Alonso; Bing Yu; Yan V Sun; Lin Y Chen; Laura R Loehr; Wesley T O'Neal; Elsayed Z Soliman; Eric Boerwinkle Journal: Am J Cardiol Date: 2019-03-18 Impact factor: 2.778
Authors: Bing Yu; Krista A Zanetti; Marinella Temprosa; Demetrius Albanes; Nathan Appel; Clara Barrios Barrera; Yoav Ben-Shlomo; Eric Boerwinkle; Juan P Casas; Clary Clish; Caroline Dale; Abbas Dehghan; Andriy Derkach; A Heather Eliassen; Paul Elliott; Eoin Fahy; Christian Gieger; Marc J Gunter; Sei Harada; Tamara Harris; Deron R Herr; David Herrington; Joel N Hirschhorn; Elise Hoover; Ann W Hsing; Mattias Johansson; Rachel S Kelly; Chin Meng Khoo; Mika Kivimäki; Bruce S Kristal; Claudia Langenberg; Jessica Lasky-Su; Deborah A Lawlor; Luca A Lotta; Massimo Mangino; Loïc Le Marchand; Ewy Mathé; Charles E Matthews; Cristina Menni; Lorelei A Mucci; Rachel Murphy; Matej Oresic; Eric Orwoll; Jennifer Ose; Alexandre C Pereira; Mary C Playdon; Lucilla Poston; Jackie Price; Qibin Qi; Kathryn Rexrode; Adam Risch; Joshua Sampson; Wei Jie Seow; Howard D Sesso; Svati H Shah; Xiao-Ou Shu; Gordon C S Smith; Ulla Sovio; Victoria L Stevens; Rachael Stolzenberg-Solomon; Toru Takebayashi; Therese Tillin; Ruth Travis; Ioanna Tzoulaki; Cornelia M Ulrich; Ramachandran S Vasan; Mukesh Verma; Ying Wang; Nick J Wareham; Andrew Wong; Naji Younes; Hua Zhao; Wei Zheng; Steven C Moore Journal: Am J Epidemiol Date: 2019-06-01 Impact factor: 4.897
Authors: Marinella Temprosa; Steven C Moore; Krista A Zanetti; Nathan Appel; David Ruggieri; Kaitlyn M Mazzilli; Kai-Ling Chen; Rachel S Kelly; Jessica A Lasky-Su; Erikka Loftfield; Kathleen McClain; Brian Park; Laura Trijsburg; Oana A Zeleznik; Ewy A Mathé Journal: Am J Epidemiol Date: 2022-01-01 Impact factor: 4.897